Potential Esophageal Cancer Treatment Tops SPT Week in Review

5. Ibrutinib Superior to Chemoimmunotherapy for Progression-Free Survival in Older CLL Patients

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia. Read more.

4. How Technology Can Foster a Seamless Patient Care Continuum

Innovations such as the Apple iPhone HealthKit could help create a smooth transition throughout the patient journey all the way to the specialty pharmacy. Read more.

3. FDA Accepts sNDAs for Expanded Use of HIV Therapies Pifeltro, Delstrigo

The new indication would allow treatment-experienced patients with HIV to switch to Pifeltro in combination with other HIV medications or Delstrigo. Read more.

2. Inhaled Parkinson Disease Drug May Signal New Era of Alternative Treatment Options

An inhaled medication for a disease that does not affect the lungs may prove to be a promising concept in the treatment of chronic diseases. Read more.

1.Keytruda Improves Survival as Second-Line Treatment for Esophageal Cancer

This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population. Read more.